Compare TransMedics Group Inc (TMDX) vs Taiwan Semiconductor Mfg. Co. Ltd. (TSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Taiwan Semiconductor Mfg. Co. Ltd. — how do they compare? TransMedics Group Inc trades at $85.89 (market cap $3.06B), while Taiwan Semiconductor Mfg. Co. Ltd. trades at $434.7 (market cap $2.03T). The key difference: Taiwan Semiconductor Mfg. Co. Ltd. is far larger — about 663.4× TransMedics Group Inc's market cap, and Taiwan Semiconductor Mfg. Co. Ltd. pays a 0.93% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | TSM | |
|---|---|---|
Market Cap | $3.06B | $2.03T |
Sector | Technology | Technology |
52-Week High | $150.42 | $477.57 |
52-Week Low | $61.99 | $258.91 |
Enterprise Value | $3.46B | $1.95T |
Dividend Yield | — | 0.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
TSM trades at $439.00, up 2.35% with strong bullish momentum. The stock shows robust fundamentals with 44.56% net margin and consistent earnings beats. Technical indicators signal bullish momentum with price near pivot point support. Recent news highlights TSMC's dominant 73% foundry market share and AI-driven growth prospects, with analyst consensus strongly bullish.
Outlook remains positive with 72% analyst buy ratings and $541.29 price target representing 23% upside. Key risks include geopolitical tensions and capital-intensive expansion, but strong cash flow generation and AI semiconductor demand support continued growth momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Taiwan Semiconductor Mfg. Co. Ltd.
Taiwan Semiconductor Manufacturing Company, or TSMC, is the world's largest dedicated chip foundry, with over 57% market share in 2021 per Gartner. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs.
Read more on TSM →
